首页> 外文OA文献 >EpCAM expression varies significantly and is differentially associated with prognosis in the luminal B HER2+, basal-like, and HER2 intrinsic subtypes of breast cancer

【2h】

EpCAM expression varies significantly and is differentially associated with prognosis in the luminal B HER2+, basal-like, and HER2 intrinsic subtypes of breast cancer

机译：EpCAM表达显着变化并且与管腔B型HER2 +，基底样和HER2内在亚型的乳腺癌预后差异相关

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Soysal Savas D; Muenst Simone; Barbie Thanh U; Fleming Timothy P; Gao Feng; Spizzo Gilbert; Oertli Daniel; Viehl Carsten T; Obermann Ellen C; Gillanders William E;
展开▼
作者单位

展开▼
年度 2013
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. EpCAM expression varies significantly and is differentially associated with prognosis in the luminal B HER2|[plus]|, basal-like, and HER2 intrinsic subtypes of breast cancer [J] . S D Soysal, S Muenst, T Barbie, British Journal of Cancer . 2013 ,第7期

机译：EpCAM表达在乳腺癌的管腔B HER2 | [plus] |，基底样和HER2内在亚型中与预后有显着差异
2. Palbociclib in combination with trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer with PAM50 luminal intrinsic subtype (SOLTI-1303 PATRICIA II): A multi-center, randomized, open-label, phase II trial [J] . Intelligence: A Multidisciplinary Journal . 2020 ,第期

机译：Palbociclib与Trastuzumab和内分泌治疗（ET）与医生的选择（TPC）与PAM50腔内在亚型（Solti-1303 Patricia II）的乳腺癌（Solti-1303）的乳腺癌（Solti-1303）：A 多中心，随机，开放标签，第二阶段试验
3. Dataset of HOXB7, HOXB8 and HOXB9 expression profiles in cell lines representative of the breast cancer molecular subtypes Luminal a (MCF7), Luminal b (BT474), HER2+ (SKBR3) and triple-negative (MDA231, MDA468), compared to a model of normal cells (MCF10A) [J] . Simone Aparecida de Bessa Garcia, Mafalda Araújo, Renata Freitas Data in Brief . 2020 ,第2期

机译： hoxb7，hoxb8 和 hoxb9 表达曲线中的乳腺癌分子亚型腔A（mcf7），腔b（与普通细胞模型相比，BT474），HER2 +（SKBR3）和三重阴性（MDA231，MDA468）（MCF10A）
4. Radiographic Detection of HER2+ Breast Cancer Cells Immunotargeted by Gold Nanoparticles [C] . Tracie L. McGinnity, Tyler E. Curtis, Tracy Vargo-Gogola, Society for Biomaterials annual meeting and exposition . 2019

机译：金纳米颗粒免疫靶向HER2 +乳腺癌细胞的放射学检测。
5. Boron Neutron Capture Therapy for HER2+ breast cancers: A feasibility study evaluating BNCT for potential role in breast conservation therapies. [D] . Jenkins, Peter Anthony. 2012

机译：HER2 +乳腺癌的硼中子捕获疗法：评估BNCT在乳腺癌保护疗法中潜在作用的可行性研究。
6. EpCAM expression varies significantly and is differentially associated with prognosis in the luminal B HER2+ basal-like and HER2 intrinsic subtypes of breast cancer [O] . S D Soysal, S Muenst, T Barbie, 2013

机译：EpCAM表达显着变化并且与管腔B型HER2 +基底样和HER2内在亚型的乳腺癌预后差异相关
7. EpCAM expression varies significantly and is differentially associated with prognosis in the luminal B HER2+, basal-like, and HER2 intrinsic subtypes of breast cancer [O] . S D Soysal, S Muenst, T Barbie, 2013

机译：EPCAM表达显着变化，与腔B HER2 +，基础样和HER2的乳腺癌内在亚型的预后差异相关
8. Advancing Our Understanding of the Etiologies and Mutational Landscapes of Basal-Like, Luminal A, and Luminal B Breast Cancers. [R] . Li, C., Chinnaiyan, A., Porter, P. 2017

机译：推进我们对基底样，Luminal a和Luminal B乳腺癌的病因和突变景观的理解。

EpCAM expression varies significantly and is differentially associated with prognosis in the luminal B HER2+, basal-like, and HER2 intrinsic subtypes of breast cancer

著录项

相似文献

相关主题

期刊订阅